Related Experiment Video
Updated: Apr 20, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ
Alexander S Banks1, Fiona E McAllister2, João Paulo G Camporez3
1Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Abstract:
Obesity-linked insulin resistance is a major precursor to the development of type 2 diabetes. Previous work has shown that phosphorylation of PPARγ (peroxisome proliferator-activated receptor γ) at serine 273 by cyclin-dependent kinase 5 (Cdk5) stimulates diabetogenic gene expression in adipose tissues. Inhibition of this modification is a key therapeutic mechanism for anti-diabetic drugs that bind PPARγ, such as the thiazolidinediones and PPARγ partial agonists or non-agonists. For a better understanding of the importance of this obesity-linked PPARγ phosphorylation, we created mice that ablated Cdk5 specifically in adipose tissues. These mice have both a paradoxical increase in PPARγ phosphorylation at serine 273 and worsened insulin resistance. Unbiased proteomic studies show that extracellular signal-regulated kinase (ERK) kinases are activated in these knockout animals. Here we show that ERK directly phosphorylates serine 273 of PPARγ in a robust manner and that Cdk5 suppresses ERKs through direct action on a novel site in MAP kinase/ERK kinase (MEK). Importantly, pharmacological inhibition of MEK and ERK markedly improves insulin resistance in both obese wild-type and ob/ob mice, and also completely reverses the deleterious effects of the Cdk5 ablation. These data show that an ERK/Cdk5 axis controls PPARγ function and suggest that MEK/ERK inhibitors may hold promise for the treatment of type 2 diabetes.
Insights
Cyclin-dependent kinase 5 (Cdk5) normally suppresses extracellular signal-regulated kinases (ERK) to prevent insulin resistance. Inhibiting MEK/ERK improves insulin sensitivity, offering a potential treatment for type 2 diabetes.
Area of Science:
- Metabolic disease research
- Molecular endocrinology
- Diabetes pathogenesis
Background:
- Obesity-induced insulin resistance is a precursor to type 2 diabetes.
- Phosphorylation of peroxisome proliferator-activated receptor γ (PPARγ) at serine 273 by Cdk5 stimulates diabetogenic gene expression.
- Current anti-diabetic drugs targeting PPARγ inhibit this phosphorylation.
Purpose of the Study:
- To investigate the role of Cdk5 in adipose tissue on PPARγ phosphorylation and insulin resistance.
- To identify the kinases responsible for PPARγ serine 273 phosphorylation in the absence of Cdk5.
- To explore the therapeutic potential of targeting the identified kinase pathway for type 2 diabetes treatment.
Main Methods:
- Generation of mice with adipose-specific Cdk5 ablation.
- Proteomic analysis to identify activated kinases in knockout mice.
- In vivo and in vitro experiments to confirm direct phosphorylation of PPARγ by ERK.
- Pharmacological inhibition of MEK and ERK in obese mouse models.
Main Results:
- Adipose-specific Cdk5 ablation paradoxically increased PPARγ serine 273 phosphorylation and worsened insulin resistance.
- Extracellular signal-regulated kinases (ERK) were identified as activated kinases in Cdk5-ablated mice.
- ERK directly phosphorylates PPARγ at serine 273, while Cdk5 suppresses ERK activity via MEK.
- Pharmacological inhibition of MEK/ERK significantly improved insulin resistance in obese mice and rescued Cdk5 ablation effects.
Conclusions:
- An ERK/Cdk5 signaling axis critically regulates PPARγ function in adipose tissue.
- ERK-mediated phosphorylation of PPARγ contributes to insulin resistance.
- Inhibitors of MEK/ERK signaling represent a promising therapeutic strategy for type 2 diabetes.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Inhibition of Cdk Activity
Inhibition of CDK Activity
Cell Specific Gene Expression
PI3K/mTOR/AKT Signaling Pathway
GPCRs Regulate Adenylyl Cylase Activity

